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Electroconvulsive therapy (ECT) is considered to be themost effective acute treatment for
otherwise treatment resistant major depressive episodes, and has been used for over 80
years. Still, the underlyingmechanism of action is largely unknow. Several studies suggest
that ECT affects the cerebral neurotransmitters, such as gamma-aminobutyric acid
(GABA) and glutamate. Magnetic resonance spectroscopy (MRS) allows investigators
to study neurotransmitters in vivo, and has been used to study neurochemical changes
in the brain of patients treated with ECT. Several investigations have been performed
on ECT-patients; however, no systematic review has yet summarized these findings. A
systematic literature search based on the Prisma guidelines was performed. PubMed
(Medline) was used in order to find investigations studying patients that had been
treated with ECT and had undergone an MRS examination. A search in the databases
Embase, PsycInfo, and Web of Science was also performed, leading to no additional
records. A total of 30 records were identified and screened which resulted in 16 original
investigations for review. The total number of patients that was included in these studies,
ignoring potential overlap of samples in some investigations, was 325. The metabolites
reported were N-acetyl aspartate, Choline, Myoinositol, Glutamate and Glutamine, GABA
and Creatine. The strongest evidence for neurochemical change related to ECT, was
found for N-acetyl aspartate (reduction), which is a marker of neuronal integrity. Increased
choline and glutamate following treatment was also commonly reported.
Keywords: depression, electroconvulsive therapy, magnetic resonance spectroscopy [(1)H MRS],
neurotransmitters, brain
INTRODUCTION
Depression is a common and debilitating psychiatric disorder. According to the World Health
Organization, more than 264 million people suffer from depression globally (1). A depressive
episode can be mild, moderate or severe, depending on the number of symptoms and their severity,
and can be part of a unipolar disorder, such as a recurrent depressive disorder or bipolar affective
disorder when accompanied by hypomania or mania (1). Electroconvulsive therapy (ECT) has
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been available for more than 80 years and is still considered
the most effective treatment for major depressive episodes. Up
to 70–90% of patients respond (>50% symptom reduction) to
the treatment in controlled trials (2, 3) and corresponding high
response rates have been found in clinical practice (4). It is in
most cases more effective than pharmacological treatment (5),
and an alternative to the 30% of patients that do not respond to
pharmacotherapy, even after several treatment steps (6).
However, the mechanism of action behind this treatment is
largely unknown. The lack of understanding may have caused
more skepticism to ECT than the treatment effect would suggest.
ECT treatment consists of electric stimulation delivered through
scalp electrodes while patients receive general anesthesia. The
electrical field from the stimulation excites neurons past their
threshold to release neurotransmitter and hereby triggers an
epileptic seizure, normally lasting 14–45 s. Muscular contraction
is avoided by use of drugs that cause neuromuscular blockade.
Typically, ECT is administrated 2–3 times a week for 3–6
weeks, but administration may vary from site to site and with
indication. The two most common ways of electrode placement
are the bitemporal (BT) placement and the right unilateral
placement (RUL) (7). Cognitive side effects impacting memory
and other cognitive domains are unfortunately common and add
to the stigma of the procedure (8). The ECT-mediated cognitive
impairment can last for weeks after an ECT series and slow
the recovery from functional impairment related to a depressive
episode (9, 10). Investigations focused on ECT’s mechanism of
action should also account for and disentangle brain changes
associated with the cognitive sequalae.
For the last 3 decades hydrogen magnetic resonance
spectroscopy (H-MRS) has helped explore the biochemical
aspects of brain changes (11). MRS takes advantage of protons
reacting slightly different to the magnetic field, depending on
their chemical environment. This makes it possible to distinguish
between different chemical compounds, and to quantify their
concentrations, even at fairly low concentrations. The metabolite
is measured in a specified volume, the voxel. The nuclear
spin of certain nuclei is measured in the voxel, and will
upon manipulation give a resonance at a certain frequency,
characteristic for a certainmetabolite. Themost common nucleus
used in MRS is the hydrogen proton (H1), but phosphorus
(31P) is another nucleus that can be measured. Figure 1 is
illustrative for a typical H1-MRS spectrum, made with the
LCModel software (12).
MRS gives the opportunity to study a broad array of
compounds in vivo in a non-invasive way. The two main
methods for H1-MRS are point resolved spectroscopy, PRESS
and stimulated echo acquisition mode, STEAM. Challenges in
MRS are overshadowing of metabolites that are present in
very small amounts by other largely abundant substances. For
gamma-aminobutyric acid (GABA) this is the case, and a special
technique is required (13, 14). MRS of the brain is primarily used
for research purposes, but is also used clinically, in newborns
with asphyxia, both in evaluation of the hypoxic-ischemic injury
and as a predictor of outcome (15, 16). MRS is also included
in the work-up of brain tumors, in some centers as a routine
exam, while in others as a supplementary tool, as it may help
in grading the tumor, decide the extension of the tumor and
as a guidance to biopsy (17). Current research will hopefully
encourage further adaptation of the method for clinical use in
fields such as psychiatry and ECT- even if current reviews so far
have concluded with conflicting results (18).
MATERIALS AND METHODS
In preparation for this review a structured literature search
was performed in the databases PubMed (25 records), Embase
(51 records), PsycInfo (16 records), and Web of Science (73
records) in December 2016. After exclusion of non-relevant
investigations and duplicates 25 investigations remained, all
of which could be found by using PubMed. Hence further
searches were performed in PubMed with the following criteria:
“(Depression OR depressive disorder) AND (electroconvulsive
therapy) AND (magnetic resonance spectroscopy)” (31 records)
and “(Major depression) AND (electroconvulsive therapy)
AND (Magnetic resonance spectroscopy)” (29 records). All
investigations on animals were excluded, as well as records
that were abstracts, publications on children and adolescents,
investigations that did not use H1-MRS and investigations
reporting manual comparisons of spectra. After exclusion 17
investigations remained, of which 13 were original investigations
included for this review. References of all investigations were
checked for additional relevant investigations. The search was
last performed on the 15th of December 2020. Three additional
investigation had been published. The literature search through
PubMed is described based on the PRISMA flowchart (19),
see Figure 2.
RESULTS
Our systematic search resulted in 16 original investigations
which were included for review, see Table 1. An overview of the
various metabolites which were investigated across all included
investigations, together with their described physiological
functions is given in Table 2. A schematic simplified overview of
the glutamine-glutamate- GABA cycle is given in Figure 3, for
illustration of how these neurotransmitters relate [adapted from
(35, 36)].
N-Acetyl Aspartate
Eleven investigations reported pre- vs. post-treatment
comparisons of NAA values. Michael et al. (27) reported
an increase of NAA in the amygdala/hippocampus region, but
this was significant only for patients that responded to ECT.
Merkl (26) reported a reduction in NAA in the dorsolateral
prefrontal cortex, but an increase in the ACC. Knudsen (20),
Cano (21) and Njau (22) and Zhang (25) all report reduced NAA
after a course of ECT-treatment, measured in the prefrontal
cortex (PFC), left hippocampus and anterior cingulate cortex
(ACC) and hippocampus, respectively. Tosun (34) also reported
reduced NAA in the ACC; however as creatine was used for
reference, the authors discuss that his was due to a relative
change in creatine. Only two studies, Njau (22) and Merkl (26),
report significantly lower levels of NAA for patients compared
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FIGURE 1 | A sample H1- MRS spectrum, created with the LCModel software. Peaks of Creatine (two peaks), myo-Inositol, Choline and N-acyl aspartate are marked.
The chemical shift (ppm) is shown on the X-axis. The Y- axis shows the intensity of the signal (measured in institutional units). The area under the curve is proportional
with the concentration of the metabolite. For GABA, a special technique is required.
to a healthy control group at baseline. Four of the published
investigations reported no significant changes in NAA: Jørgensen
(24), Pfleiderer (30) and Obergriesser (31) (long time follow up)
and Ende (32). For an overview of which investigations used
creatine ratio, see Table 1.
Choline
Nine investigations reported choline. Obergriesser (31), Ende
(32), and Zhang (25) all reported significant increase of choline,
measured in the hippocampus (Obergriesser, Ende) or ACC
(Zhang). In Obergriesser (31) the increased choline values
returned to pre-treatment values in all but one patient in post-
treatment follow up. Other investigations did not have significant
findings (21, 26, 27, 30, 34), or did not report findings (28).
Myoinsitol
Njau et al. (23) report significantly increased mI in the dorsal
ACC after ECT, while measurements from the hippocampal
voxel showed no significant change in mI. Jorgensen et al. (24)
did not find a significant change of mI when measured in the
hippocampi bilaterally.
Glutamate/Glutamine
Several previous studies on depression report reduced glutamate
or glutamate and glutamine combined (Glx) prior to treatment in
depressed subjects (37). Consistent with this, prior to treatment:
Merkl (26) and Zhang (25) do report lower values for glutamate
in patients (before treatment) compared to controls. Njau (22),
Pfleiderer (30) and Michael (28) report lower values of Glx
in patients (before treatment) compared to controls. Michael
(27) reports reduced Glx, but only in unipolar depressed
subjects compared to controls. This finding was not significant,
but trending, when including patients suffering from bipolar
disorder. After treatment, Njau (22) reports a significant increase
of Glx in the ACC. A similar result was reported by Zhang
(25) for glutamate. Pfleiderer (30) reports increased Glx only
in patients that responded to treatment. Michael et al. (28)
reports increased Glx- levels in the dorsolateral prefrontal cortex
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FIGURE 2 | Flow chart of the results of the literature search and inclusion process, based on the PRISMA flowchart.
(DLPFC), significant for responders only, but published on partly
the same material as Pfleiderer et al. (30).
Gamma-Aminobutyric Acid
Sanacora et al. (29) reported increase in occipital GABA after
treatment in 8 patients. However, there was no significant
correlation between treatment response and increase in GABA.
In 2018 Knudsen (20) replicated the study, adding a healthy
control group, but could not find any significant changes in
GABA- levels in relation to ECT. Knudsen (20) added a voxel
in the DLPFC, but could not find any significant changes in
GABA levels in this area either. In a recent study which included
41 patients from two independent sites, Erchinger et al. (33)
reported no changes in GABA levels in the ACC after ECT,
however a link to reduced performance on the effortful cognitive
processing was found in exploratory analysis.
Creatine
Eight investigations report having measured creatine. Njau (22)
reports a significant increase in creatine after treatment in the
ACC and Ende (32) reported a significant increase measured in
the hippocampus. Other investigations did not report significant
findings (24, 26, 27, 30, 31, 34).
1.28 ppm Peak
Manganas et al. (38) reported a 1.28 ppm peak in vitro and in
vivo in rats and humans. Since this peak highly correlated with
the number of neural progenitor cells in vitro, it was suggested
that this is a marker for neuronal growth. Hypothesizing that
such growth is induced by ECT, Jørgensen et al. reasoned that
this peak should be visible after ECT. However, Jørgensen et al.
(24) were not able to validate this peak in any brain region
they investigated.
DISCUSSION
Magnetic resonance spectroscopy gives us a unique possibility to
study the biochemistry in depression and ECT. The MR scan is a
gentle and non-invasive examination for the patient, demanding
only that one can lay still in a noisy and cramped environment.
Many investigations have been published on various substances,
trying to establish a link between chemical compounds and
clinical features of patients receiving ECT. Our systematic review
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suggests a reduction in N-acetyl aspartate following ECT, and
increased choline and glutamate was also commonly reported.
However, drawing firm conclusions about the effect of ECT for
individual metabolites based on the MRS literature published to
date is not possible based on diagnostic heterogeneity, concurrent
medication use, small sample sizes, and scanner/acquisition
differences. Many of the included studies have investigated both
patients suffering from bipolar disorder and a unipolar disorder.
Not all have published results segregated on type of depression.
Yet, we might speculate that since ECT has a general effect on
the brain independent of type of depression the changes we
are looking for will appear in both groups. Previous reviews
(18, 37, 39), as well as this one, have found that subjects with
depressive episodes in general display lower values of glutamate,
glutamine and/or glx, suggesting that the neurochemical changes
in different types of depression are similar. Moreover, patients
at different institutions follow different treatment regimens;
some use medication that may affect MRS findings, voxels-
placements and volumes vary, and not all of this information
might be given in the published investigations. Several techniques
have been used to study the metabolites of the brain in
the different investigations. The majority of investigations is
performed using PRESS, only one investigation not using H1-
MRS was found. Hence, most of the investigations measured
the same array of metabolites, making comparisons feasible.
However, MR- spectroscopy was performed at different time
points, both for patient groups and control groups. This could
potentially be an advantage when comparing the fluctuation
of metabolites during the course of treatment, but also makes
quantitative comparisons challenging. It has also been shown that
reference signal estimation for water when measuring GABA is
vendor specific (40), hence complicating comparisons between
different investigations.
For these reasons, and since longitudinal studies on changes
after ECT investigated by MRS are not abundant, a meta-
analysis based on the investigations included in this review
was not considered appropriate. Bearing the above-mentioned
heterogeneity in mind, there are both concordant and conflicting
results of several studies, summarized below.
NAA
Six of the eleven studies measuring NAA reported a reduction
after ECT (20–22, 25, 26), of which one discusses that the
change is due to a relative change in the reference metabolite
(34). This reduction seems to normalize with time, and was
not found in a long term follow up (31). Two studies reported
increased levels of NAA in the ACC and the hippocampus
(26, 27). Since NAA is considered a neuronal marker important
for the synthesis of myelin and in general is regarded as a
marker of neuronal integrity, it could be speculated that the
initial reduction in NAA would be associated with the cognitive
side effects. A following increase/normalization of NAA levels
could explain the alleviation of some of the side effects and
represent restorative processes occurring after ECT. However,
this hypothesis, and whether the reduction in NAA could be
associated with side effects experienced by ECT patients will need
further investigation.
Frontiers in Psychiatry | www.frontiersin.org 7 March 2021 | Volume 12 | Article 608857
Erchinger et al. MRS and Electroconvulsive Therapy
TABLE 2 | An overview of names, and supposed role/function of the most common substances investigated in this report.
Substance Putative function/role No of studies
included in review
Abbreviation Full name
NAA N-acetyl aspartate Neuronal marker, takes part in biosynthesis of myelin, marker of
formation and maintenance of myelin.
11
Cho Choline Biomarker for status of membrane phospholipid metabolism. High
levels of choline = high levels of membrane turnover.
8
mI myo-Inositol A sugar involved in regulation of neuronal osmolarity. Traditionally a
marker of glial cells, newer theory suggests that glial cells are a storage
for mI.
2
Glu, Glx Glutamate, glutamine+ glutamate The most abundant excitatory neurotransmitter. Glu has been
implicated in depression.
8
GABA gamma aminobutyric acid The most abundant inhibitory neurotransmitter. See Figure 3.
Accumulating evidence suggests role in depression. SSRI increase
GABA.
2
Cre Creatine Marker of energy metabolism. Is supposed to be relatively stable, and
is often used as reference metabolite.
8
The column to the right shows how many of the included investigations that measured a certain metabolite.
FIGURE 3 | A schematic overview illustrating the Glutamine - Glutamate-
GABA cycle. GABA is the most common inhibitory neurotransmitter in our
nervous system, while Glutamate is the most common excitatory neuro
transmitter. Cells where glutamate is synthetized from glutamine are
glutamatergic, while cells where this pathway ends in synthesis of GABA are
GABAergic. Glutamine is synthetized in the glial cell, and is then transported
into the neuron. In the neuron’s mitochondria glutamate is synthetized from
glutamine. Then glutamate is stored in synaptic vesicles (not shown).
Alternatively, GABA can be synthetized from glutamate.
Choline
All investigations examining choline reported either increased
levels (25, 31, 32) or no significant changes. Choline is a marker of
membrane turnover; an increase in choline values together with a
reduction in NAA is found in a number of brain pathologies (11).
Here, increase in Choline might reflect membrane breakdown
or increased membrane turnover (11), occurring after ECT. The
corresponding reduction in NAA levels is often interpreted as
reduced neuronal integrity and strengthens the interpretation of
increased choline after ECT as a sign of temporary disruption
caused by the ECT stimulus and/or seizure.
Myo-Inositol
Of the two investigations reporting myo-Inositol one found a
significant increase (23), but only in the ACC, and not in the
hippocampus. For the hippocampi, no study found a significant
change in mI. As mI is considered a marker of glial function,
it has been suggested that these results mark an increase of
glial functioning. To conclude on the role of mI in ECT further
research is warranted.
Glutamate and Glx
Most prior studies have found that depressed subjects display
lower values of glutamate/Glx (37) compared to healthy
control subjects. The above-mentioned investigations comparing
patients and healthy controls before ECT treatment are in
accordance with these findings, but sometimes only for a
subgroup of the patients, such as only unipolar depressed patients
(27). We found that after treatment, glutamate or glx were
either unchanged or increased (22, 25). A significant increase
correlated with the treatment response of patients in two studies
(27, 30). These findings suggest the involvement of glutamate in
the antidepressant effect of ECT. However, in one of the studies
(Njau et al.) the patients were also treated with ketamine (22),
which affects the NMDA-type glutamate receptor and might be a
confounder in that study.
GABA
Only three studies investigating GABA and ECT were identified.
The first investigation showed an increase in GABA levels
with ECT (29), but the two other studies failed to reproduce
this (20, 33). Knudsen et al. (20) tried to replicate the first
investigation, by measuring GABA also in the occipital cortex,
with an increased number of patients and adding a control group.
Erchinger et al. (33) included 41 patients and 35 controls from
two independent sites, and while no significant change in GABA
after ECT was found, exploratory analyses suggested a possible
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link between GABA levels and side effects (effortful cognitive
processing) after ECT. In summary, evidence for GABA change
after ECT is sparse, and even the initial study which reported
a significant increase in GABA failed to find a correlation of
outcome andGABA levels (29). However, with conflicting results,
more research may still be warranted, since low GABA values
have previously been reported in depression (20).
Creatine
Creatine is a marker of energy metabolism and considered
relatively stable. However, some of the investigations (22,
32) showed a significant change in creatine in the course
of ECT treatment. Njau (22) hypothesized an activation of
the corticolimbic network, with their finding of increased
creatine in the ACC. Creatine is often used as a reference
metabolite, as it is more stable between scanners when
compared to water (40). However, if ECT itself impacts
creatine concentrations, the observed change may be driven
by changes in the reference signal, rather than the metabolite
of interest.
One other metabolite, showing a peak at 1.28 ppm was
included in our review, due to one investigation (24) trying
to replicate a marker suggested of showing neurogenesis (38).
This assumption has been met with skepticism by the MRS
community (41, 42), and the investigations supporting this
hypothesis are few, and based on assumptions drawn from cell-
cultures and animal studies. The included investigation could
not find such a peak in relation to ECT, and the existence of an
MRS peak reflecting neurogenesis has not been confirmed by any
other investigation.
In summary, this literature review suggests changes of
metabolite levels, such as reduction of NAA and increase
of choline and glutamate/Glx following ECT treatment. Most
studies found no change in GABA. These findings must,
however, be compared with care, as the ECT procedure
(including indication, administration and anesthesia, as well
as time points for the MRS measurements) may vary. The
current investigations may also suggest that there could be
fluctuations in metabolites in the course of treatment with
ECT, as several studies find reduced NAA in the short term
after ECT followed by an increase (normalization) at later
follow up time points. This is, however, difficult to explore,
due to lack of detailed methodology in several of the published
investigations. For most of the metabolites, such as GABA,
more research is warranted before any firm conclusions can
be drawn.
Future Perspectives
MRS could have a great potential for clinical use, also in
psychiatry, if metabolites predicting ECT-treatment response,
outcome or cognitive side effects are to be identified. For most
metabolites currently investigated no such connection could be
identified, but research is heterogeneous and often published
alongside other findings, as most MRS findings appear to be
negative. This limits the level of detail given in published
investigations, which makes it even harder to summarize
the current state of MRS used on ECT patients. For many
metabolites there seem to be contradicting findings, but the now
accessible material cannot clearly distinguish between metabolite
changes during treatment course and actual contradictions.
There are also other metabolites which could be of interest,
such as glutathione, which have not yet been investigated in
this setting, but where both increase and decrease have been
reported in depression (43). Hence, more research on already
investigated and new metabolites is needed to explore the
relevance and benefit of clinical use of MRS in treatment of
depression. Future research focused on ECT’s mechanisms of
action should also investigate brain changes associated with
cognitive side effects, as these side effects could parallel with
neurochemical changes.
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